EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic newborn and population screening: what osteogenesis imperfecta teaches us about the promise and perils of genomic screening

Meena Balasubramanian iD

Disease Models & Mechanisms · 01.11.2026 · 19 (11)

DOI: 10.1242/dmm.053225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, online erschienen am 09.11.2026. Verfasst von Meena Balasubramanian. Beteiligte Einrichtung: Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield S10 2RX, UK. Hauptthemen laut MEDLINE: Genetic Testing, Genomics, Neonatal Screening, Osteogenesis Imperfecta. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genomic newborn and population screening is rapidly moving from pilot to policy. England's Generation Study has already enrolled tens of thousands of babies, and NHS England has committed to offering whole-genome sequencing to every newborn within a decade. Several such international initiatives, from programmes in Massachusetts and New York to Guangdong, are rapidly expanding gene panels. This expansion, however, is associated with a growing risk of over-calling genomic variants in asymptomatic infants, for whom traditional phenotype-first diagnostic models no longer apply. Osteogenesis imperfecta (OI) provides an instructive test case. It has been long treated as a textbook example of a highly penetrant Mendelian disease; however, population-scale data now show that a substantial proportion of adults carrying ‘pathogenic’ COL1A1/COL1A2 variants have no recorded clinical diagnosis of OI. Using OI as an exemplar, this article explores what genomic screening programmes can realistically deliver, identifies other conditions sharing this penetrance gap, and outlines how programmes can expand without eroding public trust.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingGenomicsNeonatal ScreeningOsteogenesis ImperfectaHumansInfant, Newborn

Autor:innen und Institutionen

  • Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield S10 2RX, UK.
  • Sheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield S10 2TH, UK.
  • Highly Specialised Service for Severe, Complex and Atypical OI, Sheffield Children's NHS Foundation Trust, Sheffield S10 2TH, UK.

ORCID-Profile: Meena Balasubramanian

Zitieren

APA

Balasubramanian, M. (2026). Genomic newborn and population screening: what osteogenesis imperfecta teaches us about the promise and perils of genomic screening. Disease Models & Mechanisms, 19(11). https://doi.org/10.1242/dmm.053225

Vancouver

Balasubramanian M. Genomic newborn and population screening: what osteogenesis imperfecta teaches us about the promise and perils of genomic screening. Disease Models & Mechanisms. 2026;19(11). doi:10.1242/dmm.053225

BibTeX
@article{Balasubramanian2026,
  author = {Balasubramanian, Meena},
  title = {Genomic newborn and population screening: what osteogenesis imperfecta teaches us about the promise and perils of genomic screening},
  journal = {Disease Models & Mechanisms},
  year = {2026},
  volume = {19},
  number = {11},
  doi = {10.1242/dmm.053225}
}
Kostenlos starten →